Podcasts
CAR T-cell therapy and precision medicine in non-Hodgkin lymphoma
Precision medicine provides an array of benefits for the treatment of non-Hodgkin lymphoma patients, but it also has its challenges….
MRD testing in multiple myeloma: new technology with promising clinical applications
Determining measurable residual disease (MRD) status is undoubtedly proving to be an effective method of prognostication and measurement of response…
CAR T-cells in myeloma: exploratory targets, payment models & treatment sequence
CAR T-cell therapy presents the opportunity to completely revolutionize the treatment of multiple myeloma, with research currently exploring the optimal…
Patient discussion at EHA 2018: CAR T-cells and MRD in CLL
CAR T-cells have demonstrated impressive efficacy in a variety of hematological malignancies, but their use in chronic lymphocytic leukemia (CLL)…
CLL therapies today: novel agents, combinations & the future of the field
Chronic lymphocytic leukemia (CLL) is experiencing a revolution in its treatment approaches. New therapies are constantly in development, and the…
CAR T-cell therapy: where are we now and what’s in store for the future?
Over the last several years, CAR T-cell therapy has emerged as a revolution in immunotherapy, with incredible results to date….
Focus on MRD: current landscape and future questions in hemonc
Measurable residual disease (MRD) has been a hot topic of interest due to its potential applications in the clinical setting….
Acute leukemias discussion: what does genomics and epigenomics tell us about patient management?
A stimulating session on the implications of genomic data for the management of acute myeloid leukemia (AML) and acute lymphoblastic…
Acute leukemias: is MRD already a surrogate for survival?
The use of minimal residual disease (MRD) in the management of acute leukemias is a hotly debated topic. Despite the…
Revolutionary immunotherapies for lymphoma
Immunotherapy has emerged in recent years as an effective novel treatment for lymphoma, with studies constantly striving to identify new…
Latest advances and current challenges in immunotherapies for lymphoma
In this lively discussion, Catherine Bollard, MBChB, MD, FRACP, FRCPA, from the Children’s National Health System and George Washington University,…
The circle of CLL: from gene discovery to targeted treatment
In this exciting feature, Carlo Croce, MD, from Ohio State University, Columbus, OH, provides an overview of the history of…
Myeloma 2017 day 2 highlights: MRD, targeted therapies and imaging advances
This is a very exciting time for multiple myeloma (MM) research, with advances in a range of areas from new…
Myeloma 2017 day 1 highlights: immunotherapy advances, a new MM subtype and liquid biopsies
Fantastic advances in immunotherapy, including CAR T-cells, bispecific antibodies and potential immunotherapy combinations, were presented at the Myeloma 2017 meeting…
Debate on the use of MRD for multiple myeloma management
The highly anticipated panel discussion on the hot topic of MRD at the Myeloma 2017 meeting in Edinburgh, UK produced…
Popular videos
-
3:22
Is CLL curable today?Michael Hallek -
3:48
How far are we from a cure for CLL?Thomas Kipps -
3:06
Mechanism of action of venetoclax (ABT-199) and its side effectsWilliam Wierda -
13:09
Myeloma 2016: Panel discussion on novel treatmentsKeith Stewart et al. -
3:11
Highlights from the International Workshop of the German CLL Study GroupMichael Hallek
